Mast Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://masttherapeutics.com
Clinical Trials
18
Active:4
Completed:10
Trial Phases
3 Phases
Phase 1:7
Phase 2:5
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (43.8%)Phase 2
5 (31.3%)Phase 3
4 (25.0%)Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Phase 1
Completed
- Conditions
- Healthy VolunteersPharmacokinetics of VepoloxamerRenal Impaired
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02646358
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
Evaluation of Vepoloxamer in Chronic Heart Failure
Phase 2
Terminated
- Conditions
- Chronic Heart Failure
- Interventions
- Other: 5% dextrose in water
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02596477
- Locations
- 🇦🇺
Research Center, Melbourne, Victoria, Australia
Evaluation of Repeat Administration of Purified Poloxamer 188
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02449616
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
🇺🇸Joe Dimaggio Children's Hospital, Hollywood, Florida, United States
Evaluation of MST-188 in Acute Lower Limb Ischemia
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02093468
- Locations
- 🇺🇸
Research Center, Cleveland, Ohio, United States
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01790087
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found